<DOC>
	<DOCNO>NCT00516048</DOCNO>
	<brief_summary>The primary purpose study ass anti-exenatide-antibody response exenatide re-exposure measure anti-exenatide antibody incidence treatment-emergent allergy hypersensitivity reaction follow period treatment interruption , patient previously expose exenatide .</brief_summary>
	<brief_title>An Exploratory Study Effect Treatment Interruption Safety Exenatide Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Diagnosed type 2 diabetes . Have expose exenatide least 3 month previous Amylin/Lilly Studies H8OMCGWAO , H8OMCGWAP , H8OMCGWAT , H8OMCGWBA . Have interrupt exenatide treatment period least 2 month . HbA1c ≤10.5 % . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Have previously complete withdrawn study . Have take market exenatide ( Byetta ) interim period study GWAO , GWAP , GWAT , GWBA current study . Used drug weight loss ( example , Xenical® [ orlistat ] , Meridia® [ sibutramine ] , Acutrim® [ phenylpropanolamine ] , Accomplia® [ rimonabant ] , similar overthecounter medication ) within 3 month screen . Are currently treat follow excluded medication : Drugs directly affect gastrointestinal motility , include , limited : Reglan® ( metoclopramide ) , Propulsid® ( cisapride ) , chronic macrolide antibiotic . Use insulin daily dosage exceed 1 U/kg .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>Byetta</keyword>
	<keyword>antibody</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>